Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase.
Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type. BC in CML is mediated by aberrant tyrosine kinase...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 10 |
|---|---|
| Autores principales: | , |
| Formato: | algorithm review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
12/4/2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=160622692&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 160622692 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 12/4/2022 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 160622692 160622692 160622692 10.1177/11795549221139357 160622692 ppf: 1 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase. aug: au: Yohanan, Binoy George, Binsah affil: Department of Hematology/Oncology, The University of Texas Health Science Center at Houston, Houston, TX, USA sug: subj: Leukemia, Myeloid, Chronic Drug Therapy Disease Management Tyrosine Kinase Inhibitors Therapeutic Use Hematopoietic Stem Cell Transplantation ab: Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type. BC in CML is mediated by aberrant tyrosine kinase activity of the BCR::ABL fusion protein. The introduction of BCR::ABL tyrosine kinase inhibitor (TKI) has been a gamechanger in the treatment of CML and there has been a significant reduction in the incidence of BC. The main treatment goal in BC is to achieve a second CP and consolidate that with an allogeneic stem cell transplantation (SCT) in eligible patients. The outcomes in BC remain dismal even in the current era. In this review, we provide an overview of the biology and current therapeutic approach in myeloid BC. pubtype: Academic Journal doctype: algorithm review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|